LOAR Q1 2026 Earnings Massive EPS Beat Signals Strong Execution Revenue Data Not Reported Acrivon Therapeutics Q1 2026 Earnings Narrowerthanexpected loss as clinical development progresses Ducommun DCO Q1 2026 Earnings EPS Falls Short of Estimates Stock Edges Higher Dianthus Therapeutics Q1 2026 Earnings EPS Beat Driven by Cost Discipline Yet Shares Slip CRVO Q1 2026 Earnings WiderthanExpected Loss as PreClinical Stage Company Reports No Revenue TREX Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency